{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T02:56:58Z","timestamp":1761101818345},"reference-count":65,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2007,11,1]],"date-time":"2007-11-01T00:00:00Z","timestamp":1193875200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["International Journal of Cardiology"],"published-print":{"date-parts":[[2007,11]]},"DOI":"10.1016\/j.ijcard.2006.12.030","type":"journal-article","created":{"date-parts":[[2007,3,31]],"date-time":"2007-03-31T11:19:10Z","timestamp":1175339950000},"page":"188-194","source":"Crossref","is-referenced-by-count":15,"title":["Current questions regarding the use of statins in patients with coronary heart disease"],"prefix":"10.1016","volume":"122","author":[{"given":"Loukianos S.","family":"Rallidis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Lekakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dimitrios T.","family":"Kremastinos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijcard.2006.12.030_bib1","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","article-title":"Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90056 participants in 14 randomised trials of statins","volume":"366","author":"Baigent","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2006.12.030_bib2","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","article-title":"MRC\/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 20536 high-risk individuals: a randomized placebo controlled trial","volume":"360","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2006.12.030_bib3","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.amjmed.2005.11.015","article-title":"Contemporary management of dyslipidemia in high-risk patients: targets still not met","volume":"119","author":"Yan","year":"2006","journal-title":"Am J Med"},{"key":"10.1016\/j.ijcard.2006.12.030_bib4","doi-asserted-by":"crossref","first-page":"7","DOI":"10.2143\/AC.56.1.2005588","article-title":"High prevalence and suboptimal treatment of risk factors in Greek coronary patients","volume":"56","author":"Rallidis","year":"2001","journal-title":"Acta Cardiol"},{"key":"10.1016\/j.ijcard.2006.12.030_bib5","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1056\/NEJM199511163332001","article-title":"Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia","volume":"333","author":"Shepherd","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijcard.2006.12.030_bib6","first-page":"1383","article-title":"Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Sinvastatin Survival Study (4S)","volume":"344","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2006.12.030_bib7","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJM199610033351401","article-title":"The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels","volume":"335","author":"Sacks","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijcard.2006.12.030_bib8","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJM199811053391902","article-title":"Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol level","volume":"339","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijcard.2006.12.030_bib9","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1001\/jama.279.20.1615","article-title":"Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS\/TexCAPS","volume":"279","author":"Downs","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.ijcard.2006.12.030_bib10","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1001\/jama.285.19.2486","article-title":"Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)","volume":"285","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.ijcard.2006.12.030_bib11","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1001\/jama.285.13.1711","article-title":"Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. The MIRACL Study: a randomized controlled trial","volume":"285","author":"Schwartz","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.ijcard.2006.12.030_bib12","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1001\/jama.292.11.1307","article-title":"Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial","volume":"292","author":"de Lemos","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.ijcard.2006.12.030_bib13","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1056\/NEJMoa040583","article-title":"Intensive versus moderate lipid lowering with statins after acute coronary syndromes","volume":"350","author":"Cannon","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijcard.2006.12.030_bib14","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa050461","article-title":"Intensive lipid lowering with atorvastatin in patients with stable coronary disease","volume":"352","author":"LaRosa","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijcard.2006.12.030_bib15","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1001\/jama.294.19.2437","article-title":"High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial","volume":"294","author":"Pedersen","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.ijcard.2006.12.030_bib16","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1161\/01.CIR.0000133317.49796.0E","article-title":"Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines","volume":"110","author":"Grundy","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2006.12.030_bib17","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1001\/jama.294.19.2492","article-title":"The IDEAL cholesterol. Lower is better","volume":"294","author":"Cannon","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.ijcard.2006.12.030_bib18","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1056\/NEJMe058052","article-title":"Low-density lipoprotein in patients with stable coronary heart disease. Is it time to shift our goals?","volume":"352","author":"Pitt","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijcard.2006.12.030_bib19","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/j.jacc.2005.03.077","article-title":"Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes","volume":"46","author":"Ray","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ijcard.2006.12.030_bib20","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1016\/j.jacc.2005.05.086","article-title":"The potential relevance of the multiple lipid-independent (pleiotropic) effects of statins in the management of acute coronary syndromes","volume":"46","author":"Ray","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ijcard.2006.12.030_bib21","first-page":"403","article-title":"Non lipid related effects of statins","volume":"42","author":"Rallidis","year":"2001","journal-title":"Hellenic J Cardiol"},{"key":"10.1016\/j.ijcard.2006.12.030_bib22","doi-asserted-by":"crossref","first-page":"54F","DOI":"10.1016\/j.amjcard.2005.06.027","article-title":"Early time to benefit with intensive statin treatment: could it be the pleiotropic effects?","volume":"96","author":"Ray","year":"2005","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ijcard.2006.12.030_bib23","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1172\/JCI0216421","article-title":"Isoprenoids as mediators of the biological effects of statins","volume":"110","author":"Liao","year":"2002","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ijcard.2006.12.030_bib24","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1161\/01.CIR.97.12.1129","article-title":"Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors","volume":"97","author":"Laufs","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2006.12.030_bib25","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1046\/j.1365-2125.2002.01677.x","article-title":"Direct in vivo evidence of a vascular statin: a single dose of cerivastatin rapidly increases vascular endothelial responsiveness in healthy normocholesterolaemic subjects","volume":"54","author":"Omori","year":"2002","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.ijcard.2006.12.030_bib26","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1172\/JCI200113152","article-title":"HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI3-kinase\/Akt pathway","volume":"108","author":"Dimmeler","year":"2001","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ijcard.2006.12.030_bib27","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.1161\/01.CIR.0000018166.84319.55","article-title":"Statin therapy accelerates re-endothelialization: a novel effect involving mobilization and incorporation of bone marrow-derived endothelial progenitor cells","volume":"105","author":"Walter","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2006.12.030_bib28","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1111\/j.1538-7836.2004.00896.x","article-title":"Fluvastatin inhibits up-regulation of tissue factor expression by antiphospholipid antibodies on endothelial cells","volume":"2","author":"Ferrara","year":"2004","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.ijcard.2006.12.030_bib29","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0167-5273(01)00576-9","article-title":"Influence of HMG-CoA reductase inhibitors on markers of coagulation, systemic inflammation and soluble cell adhesion","volume":"82","author":"Bickel","year":"2002","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.ijcard.2006.12.030_bib30","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S0021-9150(00)00454-8","article-title":"Effect of atorvastatin and fluvastatin on the expression of plasminogen activator inhibitor type-1 in cultured human endothelial cells","volume":"152","author":"Lopez","year":"2000","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ijcard.2006.12.030_bib31","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.1161\/01.CIR.0000043029.52803.7B","article-title":"Oxidized low-density lipoprotein augments and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors limit CD40 and CD40L expression in human vascular cells","volume":"106","author":"Schonbeck","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2006.12.030_bib32","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S0735-1097(02)02718-3","article-title":"Raised serum levels of soluble CD40 ligand in patients with familial hypercholesterolemia: downregulatory effect of statin therapy","volume":"41","author":"Semb","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ijcard.2006.12.030_bib33","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1161\/01.CIR.0000153810.81187.7D","article-title":"Short-term treatment with atorvastatin reduces platelet CD40 ligand and thrombin generation in hypercholesterolemic patients","volume":"111","author":"Sanguigni","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2006.12.030_bib34","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1161\/01.CIR.0000088521.04017.13","article-title":"Soluble CD40L: risk prediction after acute coronary syndromes","volume":"108","author":"Varo","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2006.12.030_bib35","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1093\/eurheartj\/ehi705","article-title":"Long-term compliance with beta-blockers, angiotensin-converting enzyme inhibitors, and statins after acute myocardial infarction","volume":"27","author":"Gislason","year":"2006","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ijcard.2006.12.030_bib36","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/S0735-1097(02)02030-2","article-title":"ACC\/AHA\/NHLBI clinical advisory on the use and safety of statins","volume":"40","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ijcard.2006.12.030_bib37","first-page":"387","article-title":"Treating dyslipidemia with statins: the risk\u2013benefit profile","volume":"145","author":"Clark","year":"2003","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ijcard.2006.12.030_bib38","first-page":"548","article-title":"Safety of lipid lowering drugs","volume":"43","author":"Rallidis","year":"2002","journal-title":"Hellenic J Cardiol"},{"issue":"suppl III","key":"10.1016\/j.ijcard.2006.12.030_bib39","doi-asserted-by":"crossref","first-page":"III-50","DOI":"10.1161\/01.CIR.0000131519.15067.1f","article-title":"Safety of statins. Focus on clinical pharmacokinetics and drug interactions","volume":"109","author":"Bellosta","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2006.12.030_bib40","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.1161\/CIRCULATIONAHA.105.557652","article-title":"The issue of statin safety: where do we stand?","volume":"111","author":"Grundy","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2006.12.030_bib41","doi-asserted-by":"crossref","first-page":"52C","DOI":"10.1016\/j.amjcard.2005.12.010","article-title":"Statin safety: a systematic review","volume":"97","author":"Law","year":"2006","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ijcard.2006.12.030_bib42","doi-asserted-by":"crossref","first-page":"77C","DOI":"10.1016\/j.amjcard.2005.12.014","article-title":"An assessment of statin safety by hepatologists","volume":"97","author":"Cohen","year":"2006","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ijcard.2006.12.030_bib43","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.atherosclerosis.2004.01.008","article-title":"Pravastatin in patients with nonalcoholic steatohepatitis. Results of a pilot study","volume":"174","author":"Rallidis","year":"2004","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ijcard.2006.12.030_bib44","doi-asserted-by":"crossref","first-page":"69C","DOI":"10.1016\/j.amjcard.2005.12.013","article-title":"An assessment of statin safety by muscle experts","volume":"97","author":"Thompson","year":"2006","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ijcard.2006.12.030_bib45","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.amjmed.2006.02.007","article-title":"Clinical perspectives of statin-induced rhabdomyolysis","volume":"119","author":"Antons","year":"2006","journal-title":"Am J Med"},{"key":"10.1016\/j.ijcard.2006.12.030_bib46","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/S0140-6736(02)11600-X","article-title":"Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomized controlled trial","volume":"360","author":"Shepherd","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2006.12.030_bib47","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/S0002-9343(01)00705-7","article-title":"Do statins cause cancer? A meta-analysis of large randomized clinical trials","volume":"110","author":"Bjerre","year":"2001","journal-title":"Am J Med"},{"key":"10.1016\/j.ijcard.2006.12.030_bib48","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/S0140-6736(04)16936-5","article-title":"Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S)","volume":"364","author":"Strandberg","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2006.12.030_bib49","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1634\/theoncologist.11-3-306","article-title":"The role of statins in cancer therapy","volume":"11","author":"Hindler","year":"2006","journal-title":"Oncologist"},{"key":"10.1016\/j.ijcard.2006.12.030_bib50","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1056\/NEJMoa043792","article-title":"Statins and the risk of colorectal cancer","volume":"352","author":"Poynter","year":"2005","journal-title":"New Engl J Med"},{"key":"10.1016\/j.ijcard.2006.12.030_bib51","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.amjcard.2005.09.110","article-title":"Effects of statins on renal function","volume":"97","author":"Agarwal","year":"2006","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ijcard.2006.12.030_bib52","doi-asserted-by":"crossref","first-page":"82C","DOI":"10.1016\/j.amjcard.2005.12.015","article-title":"National Lipid Association Statin Safety Task Force Kidney Expert Panel. An assessment of statin safety by nephrologists","volume":"97","author":"Kasiske","year":"2006","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ijcard.2006.12.030_bib53","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1097\/01.hco.0000245741.85829.06","article-title":"The effect of statins on preservation of kidney function in patients with coronary artery disease","volume":"21","author":"Tonelli","year":"2006","journal-title":"Curr Opin Cardiol"},{"key":"10.1016\/j.ijcard.2006.12.030_bib54","doi-asserted-by":"crossref","first-page":"117","DOI":"10.7326\/0003-4819-145-2-200607180-00009","article-title":"Meta-analysis: the effect of statins on albuminuria","volume":"145","author":"Douglas","year":"2006","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ijcard.2006.12.030_bib55","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1016\/j.jacc.2004.03.046","article-title":"Optimal low-density lipoprotein is 50 to 70\u00a0mg\/dl. Lower is better and physiologically normal","volume":"43","author":"O'Keefe","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ijcard.2006.12.030_bib56","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1016\/j.jacc.2005.04.064","article-title":"Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy. A PROVE IT-TIMI 22 substudy","volume":"46","author":"Wiviot","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ijcard.2006.12.030_bib57","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1161\/01.CIR.100.3.230","article-title":"Long-term effects of pravastatin on plasma concentration of C-reactive protein","volume":"100","author":"Ridker","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2006.12.030_bib58","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa042378","article-title":"C-reactive protein levels and outcomes after statin therapy","volume":"352","author":"Ridker","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijcard.2006.12.030_bib59","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.amjcard.2006.01.062","article-title":"Coronary artery disease prognosis and C-reactive protein levels improve in proportion to percent lowering to low density lipoprotein","volume":"98","author":"O'Keefe","year":"2006","journal-title":"Am J Cardiol"},{"issue":"5A","key":"10.1016\/j.ijcard.2006.12.030_bib60","doi-asserted-by":"crossref","first-page":"61F","DOI":"10.1016\/j.amjcard.2005.07.013","article-title":"Effect of intensive lipid lowering on progression of coronary atherosclerosis: evidence for an early benefit from the Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) trial","volume":"96","author":"Nissen","year":"2005","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ijcard.2006.12.030_bib61","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1016\/j.jacc.2005.02.080","article-title":"Relative efficacy of atorvastatin 80\u00a0mg and pravastatin 40\u00a0mg in achieving the dual goals of low-density lipoprotein cholesterol <70\u00a0mg\/dl and C-reactive protein <2\u00a0mg\/l","volume":"45","author":"Ridker","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ijcard.2006.12.030_bib62","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/S0140-6736(94)92082-6","article-title":"Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS)","volume":"344","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2006.12.030_bib63","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1540-8183.2006.00097.x","article-title":"The role of statins in reversing atherosclerosis: what the latest regression studies show","volume":"19","author":"Grines","year":"2006","journal-title":"J Interv Cardiol"},{"key":"10.1016\/j.ijcard.2006.12.030_bib64","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1001\/jama.291.9.1071","article-title":"Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis","volume":"291","author":"Nissen","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.ijcard.2006.12.030_bib65","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1001\/jama.295.13.jpc60002","article-title":"Effect of very high-intensity statin therapy on regression of coronary atherosclerosis. The ASTEROID trial","volume":"295","author":"Nissen","year":"2006","journal-title":"JAMA"}],"container-title":["International Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527307003476?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527307003476?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,1,8]],"date-time":"2019-01-08T13:27:40Z","timestamp":1546954060000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167527307003476"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,11]]},"references-count":65,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2007,11]]}},"alternative-id":["S0167527307003476"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcard.2006.12.030","relation":{},"ISSN":["0167-5273"],"issn-type":[{"value":"0167-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2007,11]]}}}